Exclusive

Federal 340B Leader Moves On After 21 Months

Lt. Cmdr. Emeka Egwim headshot
U.S. Public Health Service Lieutenant Commander Emeka Egwim left his position as director of OPA at HRSA 21 months after he started.
U.S. Public Health Service Lieutenant Commander Emeka Egwim left his position as director of the federal office overseeing the 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

House Committee Approves PBM Transparency Bill with 340B Provision

The House E&C Committee on Dec. 6 unanimously approved a PBM transparency bill with a 340B program provision.
Lawmakers on a key House committee approved a pharmacy benefit manager (PBM) transparency bill on Wednesday that would require PBMs [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Unlocking Greater 340B Savings

SPONSORED CONTENT

The 340B program serves as a lifeline for many communities, allowing them to provide critical services to vulnerable, underserved patients. But unfortunately, the industry faces a spectrum of challenges, from mounting drug manufacturer restrictions to incomplete referral claims capture, which hinder a covered entity’s ability to optimize their 340B program.

To help covered entities broaden the reach of their 340B program, SUNRx, a leading 340B technology solutions company, recently acquired AuthorityRx, including the automated Advanced Claims Capture (ACC) solution. By combining the technology and expertise of the companies, SUNRx is able to provide entities greater resources to serve patients and communities.

Today, when a patient of a 340B entity visits a referral provider, the entity often loses the potential savings associated with their 340B program. In the past, identifying referral claims and other missed claims with traditional referral capture models has been a complex, often manual process that results

Read More »

Amid Record Drugmaker Refunds, No Adverse Audit Findings for Teva

Teva
The final HRSA manufacturer 340B program audit conducted in fiscal year 2023 had no adverse findings for Teva Pharmaceuticals.
The fifth and final fiscal year 2023 manufacturer audit by federal officials recently concluded with no adverse findings. Meanwhile, the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Two Senior GOP Senators Suggest 340B Linked to Generic Drug Shortages

Sen. Mike Crapo (R-Idaho), ranking member of the Senate Finance Committee, said penny pricing under 340B warranted “serious scrutiny in the context of generic products.”
Two Republican Senators on an influential committee suggested during a hearing on Tuesday that 340B discounts could contribute to certain [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

New Part B Drug Claims Modifier Requirement for 340B Entities Starts Jan. 1

CMS
In response to the ongoing Change Healthcare cyberattack, CMS will direct contractors to provide some accelerated payments to hospitals.
Critical access hospitals (CAHs) and Ryan White HIV/AIDS clinics do not expect problems implementing a new requirement starting Jan. 1, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B INDUSTRY LEADER SPOTLIGHT

Cheryl Hetland, VP of 340B Program Management, Avita Care Solutions

Cheryl Hetland

Q: Where did you grow up?

I grew up in Mt. Iron, a small town located in the Iron Range of northern Minnesota. I was raised as a country

Read More »

Expert Tip From 340Best

img
img

TIP: Create and maintain a comprehensive crosswalk or log documenting your 340B registered sites, contract pharmacies, and all associated contract pharmacy agreements.

Read More »

Four 340B Terminations, Eight Paybacks to Manufacturers in Latest Provider Audit Findings

HRSA provider audits
Federal auditors determined terminations from the 340B program were required for either covered entity sites or a contract pharmacy of two more 340B providers.
Federal auditors determined terminations from the 340B program were required for either covered entity sites or contract pharmacies of four [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Biogen Adds Drug with Narrow Approval to 340B Contract Pharmacy Restrictions

Biogen wordmark on building facade
Drugmaker Biogen recently added a third drug to its 340B contract pharmacy restrictions for hospitals.
Biopharmaceutical manufacturer Biogen recently expanded its contract pharmacy restrictions for hospitals to a third drug, after that medication garnered a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report